The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Nakayama S, Yoshizawa A, Tsurutani J, Yoshimura K, Aoki G, Iwamoto T, Nagase H, Sugimoto N, Kobayashi K, Izumi S, Kato T, Miyazaki Y, Kurihara Y, Taira N, Aihara T, Kikawa Y, Mukai H

Real-world incidence of and risk factors for abemaciclib-induced interstitial lung disease in Japan: a nested case-control study of abemaciclib-induced interstitial lung disease (NOSIDE).

Breast cancer (Tokyo, Japan). 2025;32(1):177-185

Hunt A, Haque W, Pino R, Farach A, Butler EB, Teh BS

Radiation Pneumonitis, Really? A Case of Pulmonary Toxicity from CDK4/6 Inhibitor.

Anticancer research. 2023;43(8):3539-3542

Okayasu K, Kawasaki T, Kumagai J, Miyazaki Y

Clinicoradiological course of abemaciclib-induced pneumonitis with histology findings.

BMJ case reports. 2023;16(5)

Nawa H, Niimura T, Yagi K, Goda M, Zamami Y, Ishizawa K

Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments.

Cancer reports (Hoboken, N.J.). 2022;5(1):e1402

Chen Y, Noma S, Taguchi Y, Takahashi M, Tsurutani J, Mori S, Sakaguchi S, Asou H, Tomii K

Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan.

Breast cancer (Tokyo, Japan). 2021;28(3):710-719

Jazieh KA, Budd GT, Dalpiaz N, Abraham J

Can CDK4/6 inhibitors cause fatal lung injury?

Expert review of anticancer therapy. 2019;19(11):917-919